埃万妥单抗
Anti-Human EGFRxMET Bispecific Antibody(Amivantamab; JNJ-61186372)
ChemLeader
Catalog No:
CAS No.:
MDLNo:
Formula:
MW:
Size
Quantity
- +
Product Overview
Product Name Anti-Human EGFRxMET Bispecific Antibody(Amivantamab; JNJ-61186372)
CAS2171511-58-1
Storage condition-20°C for 3 years | In solvent: -80°C for 1 year
Security information
Product details

Amivantamab (JNJ-61186372) is a fully human EGFR-MET bispecific antibody that combats resistance in NSCLC through multifaceted mechanisms: ligand blockade, receptor degradation, and immune cell activation, including ADCC and trogocytosis. This innovative approach targets both primary and acquired resistance, offering a new therapeutic avenue for patients with EGFR and MET aberrations.

Related
Sorry, no related items
History
Tuvirumab
Farletuzumab (anti-FOLR1)
Tildrakizumab (Anti-IL-23a)
Aducanumab (Anti-Amyloid-β )
Anti-Human EGFRxMET Bispecific Antibody(Amivantamab; JNJ-61186372)
Olokizumab (Anti-IL-6 / IFNb2)
Figitumumab (Anti-IGF1R / CD221)
Solanezumab (Anti-Amyloid-β)
Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262)
Anti-Human PD-1 Monoclonal Antibody(Pembrolizumab biosimilar) mAb; MK-3475; Lambrolizumab